APASL 7th Single Topic Conference “Hepatitis C Virus” Program
as of 2010/12/05
December 17th (Friday)
Opening Remarks Osamu Yokosuka (Chairman of the Conference)
Basic Research (9:00-10:00)
Chairs: Kunitada Shimotohno (Japan), Stephen Locarnini (Australia)
HCV Replication in Vitro Takaji Wakita (Japan)
Replication of HCV Stephen Locarnini (Australia)
Hepatitis C Virus Replication and Response to Anti-viral Drugs in Human Hepatocyte Chimeric Mice Kazuaki Chayama (Japan)
Epidemiology (10:00-12:30)
HCV in Asia-Pacific I (10:00-10:40)
Chairs: Yogesh Chawla (India), Saeed Hamid (Pakistan)
HCV in Egypt Gamal Shiha (Egypt)
HCV in Turkey Kadir A. Dokmeci (Turkey)
HCV Infection in Pakistan Wasim Jafri (Pakistan)
Hepatitis C in India Premashis Kar (India)
Coffee Break (10:40 – 10:50)
HCV in Asia-Pacific II (10:50-11:20)
Chairs: Anuchit Chutaputti (Thailand), Jun Qi Niu (China)
Chronic Hepatitis C in Thailand Teerha Piratvisuth (Thailand)
Hepatitis C in China Lai Wei (China)
Epidemiology of Hepatitis C Virus Infection in Mongolia
Oidov Baatarkhuu (Mongolia)
HCV in Asia-Pacific III (11:20-11:50)
Chairs: Byung Chul Yoo (Korea), Lai Wei (China)
Hepatitis C Virus Infection in Taiwan Wan-Long Chuang (Taiwan)
HCV in Korea Hyo-Suk Lee (Korea)
HCV in Japan Hiroshi Yatsuhashi (Japan)
HCV in Asia-Pacific IV (11:50-12:20)
Chairs: Seng Gee Lim (Singapore), Seung Woon Paik (Korea)
Chronic Hepatitis C Infection in the Philippines Jose D. Sollano (Philippines)
HCV in Austarlia Darrell H. Crawford (Australia)
HCV in Indonesia Laurentius A Lesmana (Indonesia)
Lunch on Seminar (12:30-13:30)
Chair: Masao Omata (Japan)
“Pegylated Interferons in the Era of Direct Antiviral Agents for Hepatitis C”
Christophe Sarrazin (Germany)
(Presented by Chugai Pharmaceutical Co., Ltd.)
Clinical Feature of Chronic Hepatitis C (13:40-14:25)
Chairs: George Lau (Hong Kong), Teerha Piratvisuth (Thailand)
Dual HCV and HBV Infection: Unique and Unresolved Issues
Pei Jer Chen (China)
Hepatitis B and C Virus Coinfection among 1036 Patients Hasan Ozkan (Turkey)
Characterization of Patients Coinfected by Hepatitis B and Hepatitis C Viruses
Gamal Shiha (Egypt)
Clinical Feature of Chronic Hepatitis C 14:25-14:55
Chairs: Jun Cheng (China), Premashis Kar (India)
HIV and HCV Coinfection Gregory Dore (Australia)
Liver Transplantation and HCV Geoff McCaughan (Australia)
Coffee Break (14:55-15:05)
Treatment of Chronic Hepatitis C (15:05-16:50)
Factors Influencing the IFN/Ribavirin Therapy I: Viral Factors (15:05-15:50)
Chairs: Hyo Suk Lee (Korea), Darrell H. Crawford (Australia)
Viral Genetic Elements and Host Genetic Factors in Response to Peginterferon plus Ribavirin Therapy in HCV-1b infection Nobuyuki Enomoto (Japan)
Amino Acid Substitutions in HCV Core Region of Genotype 1b are the Important Viral Predictors of Treatment Resistance and Hepatocarcinogenesis
Norio Akuta (Japan)
Hepatitis C: Response Guided Therapy Today and Tomorrow
Christoph Sarrazin (Germany)
Factors Influencing the IFN/Ribavirin Therapy II: Human Factors (15:50-16:20)
Chairs: Dong Jin Suh (Korea), Yutaka Sasaki (Japan)
Innate Immunity Stephen Locarnini (Australia)
Molecular Analyses of Interferon Resistance by using HCV Cell Culture Systems
Naoya Sakamoto (Japan)
Factors Influencing the IFN/Ribavirin Therapy III: IL28B (16:20-16:50)
Chairs: Osamu Yokosuka (Japan), Wasim Jafri (Pakistan)
Association of Genetic Variation in IL28B with the Hepatitis C Treatment-induced Viral Clearance in the Chinese Han Population Xinxin Zhang (China)
Genetic Variation in IL-28B is Associated with Response to Interferon Therapy for Chronic Hepatitis C Yasuhito Tanaka (Japan)
Evening Seminar (17:00-18:00)
Chair: Dong Jin Suh (Korea)
“Delivering Individual Success in Patients with Hepatitis C”
Michael Manns (Germany)
(Presented by MSD K.K.)
Poster Presentation & Discussion (18:00-19:00)
 Poster Program
Conference Welcome Reception for all the participants at International Conference Room, 2F
December 18th (Saturday)
Morning Seminar (8:00-9:00)
Chair: Takafumi Ichida (Japan)
“Topics of Hepatitis Virus ～HBV Reactivation and IL28B for HCV Treatment～”
Masashi Mizokami (Japan)
(Presented by Bristol Myers K.K.)
Factors Influencing the IFN/Ribavirin Therapy IV: Changes Caused by HCV Infection (9:10 -9:55)
Chairs: Kadir Dokmeci (Turkey), Shiv Kumar Sarin (India)
Factors Influencing the IFN/Ribavirin Therapy Tentative Yogesh Chawla (India)
HCV-induced Oxidative Stress and Metabolic Disorder Keisuke Hino (Japan)
Gene Expression in HCV Infection Masao Honda (Japan)
Factors Influencing the IFN/Ribavirin Therapy V: Treatment Device (9:55-10:40)
Chairs: Masashi Mizokami (Japan), Wan-Long Chuang (Taiwan)
HCV Infection and Metabolic Syndrome Jun Cheng (China)
Standard IFN/Ribavirin therapy Jia Horng Kao (Taiwan)
Prolonged Pegylated Interferonα-2b Plus Ribavirin Therapy for Chronic Hepatitis C Patients of Genotype 1b Jun Hayashi (Japan)
Coffee Break (10:40-10:55)
New HCV Therapy and HCV Guideline (10:55-11:55)
Chairs: Masao Omata (Japan), Michael Manns (Germany)
Hepatitis C Protease Inhibitors 2010 Michael Manns (Germany)
New Antiviral Drugs Averell H. Sherker (USA)
Combination Therapy with Polymerase and Protease Inhibitors
Edward Gane (New Zealand)
Necessity for New HCV Guideline Geoff W. McCaughan (Australia)
Lunch on Seminar 2 (12:00-13:30) at Conference Room 1
“Molecular of Intermediate and Advanced Hepatocellular Carcinoma”
Chair: Masatoshi Kudo (Japan)
Joong Won Park (Korea)
Ann-Lii Cheng (Taiwan)
(Presented by Bayer Yakuhin Ltd.)
Lunch on Seminar 3 (12:00-13:00) at Conference Room 2
Chair: Hiroshi Yatsuhashi (Japan)
Shuhei Nishiguchi (Japan)
Kazuhiko Hayashi (Japan)
Masaru Enomoto (Japan)
(Presented by Otsuka Pharmaceutical Co., Ltd.)
HCV and HCC I (13:40-14:25)
Chairs: Jose D. Sollano (Philippines), Hiromi Ishibashi (Japan)
Hepatocarcinogenesis in Hepatitis C Viral Infection Kazuhiko Koike (Japan)
Gene Expressinos in HCV Infection Shuichi Kaneko (Japan)
Molecular Targeting Therapy Masatoshi Kudo (Japan)
HCV and HCC II (14:25-14:55)
Chairs: Laurentius A Lesmana (Indonesia), Goshi Shiota (Japan)
Impact of Aging for the Development of Hepatocellular Carcinoma (HCC) and Reduced Response to Peginterferon and Ribavirin Combination Therapy
Namiki Izumi (Japan)
Treatment Algorism for Hepatocellular Carcinoma
Joong Won Park (Korea)
Plenary Poster Session (Oral Presentation) (15:00-15:40)
Chairs: Seung Woon Paik (Korea), Eiji Tanaka (Japan)
(Abstract No. 10076) Sadia Butt (Pakistan)
(Abstract No. 10024) Goshi Shiota (Japan)
(Abstract No. 10051) Sang Jong Park (Korea)
(Abstract No. 10065) Ming-Lung Yu (Taiwan)
Closing Remarks Osamu Yokosuka (Chairman of the Conference) |
